Skip to content
Triangle logo TriangleGet started
← Non-Small Cell Lung Cancer

TREATMENT READING

Non-Small Cell Lung Cancer, part 4

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

230 sections
  1. Treatment Option Overview for NSCLC
  2. Treatment of Occult NSCLC
  3. Treatment Options for Occult NSCLC
  4. Treatment of Stage 0 NSCLC
  5. Treatment Options for Stage 0 NSCLC
  6. Surgery
  7. Endobronchial therapies
  8. Treatment of Stages IA and IB NSCLC
  9. Treatment Options for Stages IA and IB NSCLC
  10. Surgery
  11. Adjuvant therapy
  12. Adjuvant chemotherapy
  13. Adjuvant targeted therapy (for patients with stage IB NSCLC and EGFR variants)
  14. Adjuvant targeted therapy (for patients with stage IB tumors and ALK variants)
  15. Adjuvant immunotherapy
  16. Adjuvant external radiation therapy
  17. Adjuvant brachytherapy
  18. Radiation therapy
  19. Conventional radiation therapy
  20. Hypofractionated radiation therapy
  21. Stereotactic body radiation therapy (SBRT)
  22. Treatment of Stages IIA and IIB NSCLC
  23. Treatment Options for Stages IIA and IIB NSCLC
  24. Surgery with or without adjuvant or neoadjuvant therapy
  25. Surgery alone
  26. Adjuvant chemotherapy
  27. Adjuvant targeted therapy (for patients with EGFR variants)
  28. Adjuvant targeted therapy (for patients with ALK variants)
  29. Adjuvant immunotherapy
  30. Adjuvant radiation therapy
  31. Neoadjuvant chemotherapy
  32. Neoadjuvant immunotherapy with chemotherapy
  33. Nivolumab plus platinum-based chemotherapy
  34. Perioperative (neoadjuvant and adjuvant) immunotherapy with chemotherapy
  35. Perioperative pembrolizumab plus platinum-based chemotherapy
  36. Perioperative durvalumab plus platinum-based chemotherapy
  37. Perioperative nivolumab plus platinum-based chemotherapy
  38. Perioperative toripalimab plus platinum-based chemotherapy
  39. Radiation therapy
  40. Treatment of Stage IIIA NSCLC
  41. Treatment Options for Resected/Resectable Stage IIIA NSCLC
  42. Surgery
  43. Neoadjuvant therapy
  44. Neoadjuvant chemotherapy
  45. Neoadjuvant chemoradiation therapy
  46. Neoadjuvant immunotherapy with chemotherapy
  47. Nivolumab plus platinum-based chemotherapy
  48. Perioperative (neoadjuvant and adjuvant) immunotherapy with chemotherapy
  49. Perioperative pembrolizumab plus platinum-based chemotherapy
  50. Perioperative durvalumab plus platinum-based chemotherapy
  51. Perioperative nivolumab plus platinum-based chemotherapy
  52. Perioperative toripalimab plus platinum-based chemotherapy
  53. Adjuvant therapy
  54. Adjuvant chemotherapy
  55. Adjuvant targeted therapy (for patients with EGFR variants)
  56. Adjuvant targeted therapy (for patients with ALK variants)
  57. Adjuvant immunotherapy
  58. Adjuvant chemoradiation therapy
  59. Adjuvant radiation therapy
  60. Treatment Options for Unresectable Stage IIIA NSCLC
  61. Chemoradiation therapy
  62. Concurrent versus sequential chemoradiation therapy
  63. Radiation therapy dose escalation for concurrent chemoradiation
  64. Consolidation therapy following concurrent chemoradiation
  65. Consolidation immunotherapy
  66. Durvalumab
  67. Osimertinib (for patients with EGFR variants)
  68. Other systemic consolidation therapies
  69. Radiation therapy
  70. Locally advanced unresectable tumors
  71. Palliative treatment
  72. Treatment Options for Superior Sulcus Tumors
  73. Surgery
  74. Chemoradiation therapy followed by surgery
  75. Radiation therapy dose escalation for concurrent chemoradiation
  76. Radiation therapy alone
  77. Treatment Options for Tumors That Invade the Chest Wall
  78. Treatment of Stages IIIB and IIIC NSCLC
  79. Treatment Options for Stages IIIB and IIIC NSCLC
  80. Sequential or concurrent chemotherapy and radiation therapy
  81. Radiation therapy dose escalation for concurrent chemoradiation
  82. Systemic consolidation therapy before or after concurrent chemoradiation therapy
  83. Consolidation immunotherapy
  84. Durvalumab
  85. Osimertinib (for patients with EGFR variants)
  86. Other systemic consolidation therapies
  87. Radiation therapy alone
  88. For treatment of locally advanced unresectable tumor in patients who are not candidates for chemotherapy
  89. For patients requiring palliative treatment
  90. Treatment of Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC
  91. Factors Affecting Treatment Selection
  92. History and molecular features
  93. Age and comorbidity
  94. Performance status
  95. Treatment Options for Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC (First-Line Therapy)
  96. Cytotoxic combination chemotherapy
  97. Combination chemotherapy
  98. Drug and dose schedule
  99. Combination chemotherapy with monoclonal antibodies
  100. Bevacizumab
  101. Cetuximab
  102. Necitumumab
  103. Maintenance therapy after first-line chemotherapy (for patients with stable or responding disease after four cycles of platinum-based combination chemotherapy)
  104. EGFR tyrosine kinase inhibitors (TKIs) with or without chemotherapy (for patients with EGFR variants)
  105. Osimertinib alone
  106. Osimertinib plus chemotherapy
  107. Amivantamab plus lazertinib
  108. Dacomitinib
  109. Gefitinib
  110. Erlotinib
  111. Afatinib
  112. EGFR-directed therapy (for patients with EGFR exon 20 insertions)
  113. Amivantamab
  114. ALK inhibitors (for patients with ALK translocations)
  115. Alectinib
  116. Lorlatinib
  117. Crizotinib
  118. Ceritinib
  119. Brigatinib
  120. BRAF V600E and MEK inhibitors (for patients with BRAF V600E variants)
  121. Dabrafenib and trametinib
  122. ROS1 inhibitors (for patients with ROS1 rearrangements)
  123. Entrectinib
  124. Crizotinib
  125. Repotrectinib (for both ROS1 TKI-naïve and ROS1 TKI-treated patients)
  126. NTRK inhibitors (for patients with NTRK fusions)
  127. Larotrectinib
  128. Entrectinib
  129. RET inhibitors (for patients with RET fusions)
  130. Selpercatinib
  131. Pralsetinib
  132. MET inhibitors (for patients with MET exon 14-skipping variants)
  133. Tepotinib
  134. Capmatinib
  135. Immune checkpoint inhibitors with or without chemotherapy
  136. Pembrolizumab plus chemotherapy
  137. Pembrolizumab alone
  138. Cemiplimab-rwlc plus chemotherapy
  139. Cemiplimab-rwlc alone
  140. Tremelimumab
  141. Durvalumab plus tremelimumab plus chemotherapy
  142. Atezolizumab alone
  143. Atezolizumab plus chemotherapy
  144. Atezolizumab plus bevacizumab plus chemotherapy
  145. Nivolumab plus ipilimumab
  146. mTOR inhibitors
  147. Everolimus
  148. Local therapies and special considerations
  149. Endobronchial laser therapy and/or brachytherapy (for obstruction lesions)
  150. EBRT (primarily for palliation of local symptomatic tumor growth)
  151. Treatment of second primary tumor
  152. Treatment of brain metastases
  153. Treatment of Progressive Stage IV, Relapsed, and Recurrent NSCLC
  154. Treatment Options for Progressive Stage IV, Relapsed, and Recurrent NSCLC (Second-Line Therapy)
  155. Chemotherapy
  156. Docetaxel
  157. Docetaxel plus ramucirumab
  158. Datopotamab deruxtecan
  159. Pemetrexed
  160. EGFR-directed therapy
  161. EGFR-directed therapy after first-line chemotherapy (for patients with EGFR-sensitizing variants)
  162. Erlotinib
  163. Gefitinib
  164. Afatinib
  165. EGFR-directed therapy (for patients with acquired EGFR T790M variants after previous EGFR-directed therapy)
  166. Osimertinib
  167. EGFR-directed therapy after first-line chemotherapy (for patients with EGFR exon 20 insertions)
  168. Amivantamab
  169. Amivantamab plus chemotherapy
  170. Subcutaneous amivantamab-lazertinib
  171. ALK-directed TKIs
  172. ALK-directed TKIs after first-line chemotherapy
  173. Crizotinib
  174. ALK-directed TKIs after prior ALK TKI therapy
  175. Ceritinib
  176. Alectinib
  177. Brigatinib
  178. Lorlatinib
  179. BRAF V600E and MEK inhibitors (for patients with BRAF V600E variants)
  180. Dabrafenib and trametinib
  181. ROS1-directed therapy
  182. Entrectinib
  183. Crizotinib
  184. Repotrectinib (for both ROS1 TKI-naïve and ROS1 TKI-treated patients)
  185. NTRK inhibitors (for patients with NTRK fusions)
  186. Larotrectinib
  187. Entrectinib
  188. RET inhibitors (for patients with RET fusions)
  189. Selpercatinib
  190. Pralsetinib
  191. MET inhibitors (for patients with MET exon 14-skipping variants)
  192. Tepotinib
  193. Capmatinib
  194. KRAS G12C inhibitors (for patients with KRAS G12C variants)
  195. Adagrasib
  196. Sotorasib
  197. HER2-targeted therapy (for patients with HER2 variants)
  198. Trastuzumab deruxtecan
  199. Immunotherapy
  200. Nivolumab
  201. Pembrolizumab
  202. Atezolizumab
  203. mTOR inhibitors
  204. Everolimus
  205. Certain factors affect the prognosis (chance of recovery) and treatment options.
  206. Non-small cell lung cancer can recur (come back) after it has been treated.
  207. Treatment Option Overview
  208. Key Points
  209. There are different types of treatment for people with non-small cell lung cancer.
  210. The following types of treatment are used:
  211. Surgery
  212. Radiation therapy
  213. Chemotherapy
  214. Targeted therapy
  215. Immunotherapy
  216. Laser therapy
  217. Photodynamic therapy (PDT)
  218. Cryosurgery
  219. Electrocautery
  220. New types of treatment are being tested in clinical trials.
  221. Treatment for non-small cell lung cancer may cause side effects.
  222. Follow-up care may be needed.
  223. Treatment of Occult Non-Small Cell Lung Cancer
  224. Treatment of Stage 0 (carcinoma in situ)
  225. Treatment of Stage I Non-Small Cell Lung Cancer
  226. Treatment of Stage II Non-Small Cell Lung Cancer
  227. Treatment of Stage IIIA Non-Small Cell Lung Cancer
  228. Treatment of Stage IIIB and Stage IIIC Non-Small Cell Lung Cancer
  229. Treatment of Newly Diagnosed Stage IV, Relapsed, and Recurrent Non-Small Cell Lung Cancer
  230. Treatment of Progressive Stage IV, Relapsed, and Recurrent Non-Small Cell Lung Cancer

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Studies

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

NCT04035486 · ACTIVE NOT RECRUITING · phase3

Non-Small Cell Lung Cancer

ClinicalTrials.gov record

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

NCT04158440 · COMPLETED · phase3

Stage II-III Non-small Cell Lung Cancer

ClinicalTrials.gov record

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

NCT04194944 · ACTIVE NOT RECRUITING · phase3

Non-Small Cell Lung Cancer

ClinicalTrials.gov record

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT04222972 · TERMINATED · phase3

RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung...

ClinicalTrials.gov record

ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting

NCT04241315 · COMPLETED · phase3

Lung Neoplasms, Lung Cancer

ClinicalTrials.gov record

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

NCT04303780 · COMPLETED · phase3

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

ClinicalTrials.gov record

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

NCT04395677 · ACTIVE NOT RECRUITING · phase2

Non Small Cell Lung Cancer

ClinicalTrials.gov record

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

NCT04484142 · COMPLETED · phase2

Non-small Cell Lung Cancer

ClinicalTrials.gov record

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080 · ACTIVE NOT RECRUITING · phase3

Carcinoma, Non-Small-Cell Lung

ClinicalTrials.gov record

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664 · ACTIVE NOT RECRUITING · phase3

Carcinoma, Non-Small-Cell Lung

ClinicalTrials.gov record

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT04644237 · COMPLETED · phase2

Non-Small Cell Lung Cancer

ClinicalTrials.gov record

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

NCT04656652 · ACTIVE NOT RECRUITING · phase3

Non-small Cell Lung Cancer

ClinicalTrials.gov record

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135 · ACTIVE NOT RECRUITING · phase3

Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer

ClinicalTrials.gov record

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804 · ACTIVE NOT RECRUITING · phase1

Neoplasm Metastasis, Non-Small Cell Lung Cancer

ClinicalTrials.gov record

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811 · ACTIVE NOT RECRUITING · phase2

Non Small Cell Lung Cancer

ClinicalTrials.gov record

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295 · ACTIVE NOT RECRUITING · phase3

Carcinoma, Non-Small-Cell Lung

ClinicalTrials.gov record

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172 · RECRUITING · phase1, phase2

Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

ClinicalTrials.gov record

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

NCT05388669 · ACTIVE NOT RECRUITING · phase3

Advanced or Metastatic Non-small Cell Lung Cancer

ClinicalTrials.gov record

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

NCT05460273 · ACTIVE NOT RECRUITING · phase1, phase2

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer

ClinicalTrials.gov record

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

NCT05722015 · ACTIVE NOT RECRUITING · phase3

Metastatic Non-small Cell Lung Cancer

ClinicalTrials.gov record

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

NCT06099782 · ACTIVE NOT RECRUITING · phase2

Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma

ClinicalTrials.gov record

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

NCT00128102 · COMPLETED · phase3

Mesothelioma, Lung Cancer

ClinicalTrials.gov record

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

NCT00253708 · COMPLETED · na

Cancer

ClinicalTrials.gov record

Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen

NCT00316225 · COMPLETED · phase2

Non-small Cell Lung Cancer, Mesothelioma, Lung Neoplasms

ClinicalTrials.gov record

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

NCT00398138 · COMPLETED · phase1

Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer

ClinicalTrials.gov record

Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)

NCT00423150 · TERMINATED · phase2

Colorectal Neoplasm, Head and Neck Neoplasm, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasm

ClinicalTrials.gov record

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

NCT00441337 · COMPLETED · phase1

Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer

ClinicalTrials.gov record

CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)

NCT00748085 · TERMINATED · na

Lung Cancer, Mesothelioma

ClinicalTrials.gov record

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

NCT00753415 · COMPLETED · phase1

Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma, Colon Carcinoma, Renal Cell Carcinoma, Bladder Carcinoma, Prostate Cancer

ClinicalTrials.gov record

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

NCT00819169 · TERMINATED · phase1, phase2

Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Solid Tumors

ClinicalTrials.gov record

A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...

NCT00923481 · COMPLETED · phase2

Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

ClinicalTrials.gov record

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

NCT01059643 · COMPLETED · phase2

Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cancer of Head and Neck

ClinicalTrials.gov record

A Study in Non Small Cell Lung Cancer

NCT01139775 · COMPLETED · phase1, phase2

Non Small Cell Lung Cancer

ClinicalTrials.gov record

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

NCT01177397 · COMPLETED · phase1, phase2

Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin,...

ClinicalTrials.gov record

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

NCT01327612 · COMPLETED · phase2

Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced, Lymphoma, Metastatic Cancer, Non-Small Cell Lung Cancer, Sarcoma, Solid Tumors

ClinicalTrials.gov record

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT01390818 · COMPLETED · phase1

Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Melanoma, Colorectal Cancer

ClinicalTrials.gov record

Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies

NCT01401907 · COMPLETED · na

Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Esophageal Cancer, Gastric Cancer, Liver Cancer, Pancreatic Cancer

ClinicalTrials.gov record

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

NCT01423760 · TERMINATED · na

Non-Small Cell Lung Cancer, Multiple Myeloma

ClinicalTrials.gov record

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

NCT01451632 · COMPLETED · phase1

Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other Tumors With EGFR Dependence

ClinicalTrials.gov record

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

NCT01457417 · COMPLETED · phase1

Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer

ClinicalTrials.gov record

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

NCT01567722 · TERMINATED · Phase not reported

Lung Cancer, Lymphoma

ClinicalTrials.gov record

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

NCT01583686 · TERMINATED · phase1, phase2

Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Lung Cancer

ClinicalTrials.gov record

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

NCT01647711 · COMPLETED · phase1

Carcinoma, Non-Small-Cell Lung

ClinicalTrials.gov record

Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer

NCT01676714 · COMPLETED · phase2

Non-Small Cell Lung Cancer, Colorectal Cancer

ClinicalTrials.gov record

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

NCT01761240 · COMPLETED · phase1

Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma

ClinicalTrials.gov record

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

NCT01803282 · COMPLETED · phase1

Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer

ClinicalTrials.gov record

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

NCT02009449 · COMPLETED · phase1

Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer

ClinicalTrials.gov record

A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body

NCT02014116 · TERMINATED · phase1

Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

ClinicalTrials.gov record

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

NCT02062632 · TERMINATED · phase2

Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma, Mesothelioma, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the...

ClinicalTrials.gov record

A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy

NCT02130427 · COMPLETED · na

Biopsy Proven Non Small Cell Lung Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Colorectal Cancer, Rectal Cancers, Gynecological Malignancy Requiring Definitive...

ClinicalTrials.gov record

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

NCT02293005 · COMPLETED · phase2

Lung Cancer, Mesothelioma

ClinicalTrials.gov record

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

NCT02347917 · COMPLETED · phase1, phase2

Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer

ClinicalTrials.gov record

Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers

NCT02349412 · COMPLETED · phase3

Liver Cancer, Anxiety Disorder, Depression, Small Cell Lung Cancer, Extrahepatic Bile Duct Cancer, Malignant Mesothelioma, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer,...

ClinicalTrials.gov record

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

NCT02408016 · TERMINATED · phase1, phase2

Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma, Stage III...

ClinicalTrials.gov record

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

NCT02443324 · COMPLETED · phase1

Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer

ClinicalTrials.gov record

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

NCT02452424 · TERMINATED · phase1, phase2

Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer

ClinicalTrials.gov record

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT02457793 · COMPLETED · phase1

Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma

ClinicalTrials.gov record

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903 · COMPLETED · phase2

Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer

ClinicalTrials.gov record

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

NCT02526017 · COMPLETED · phase1

Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer

ClinicalTrials.gov record

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NCT02573259 · COMPLETED · phase1

Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA

ClinicalTrials.gov record

18F-FSPG PET/CT for Cancer Patients on Therapy

NCT02599194 · COMPLETED · phase2

B-Cell Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Renal Cell Cancer, Progesterone Receptor Negative, Stage III Mesothelioma, Stage III Renal Cell...

ClinicalTrials.gov record

PF-06671008 Dose Escalation Study in Advanced Solid Tumors

NCT02659631 · TERMINATED · phase1

Neoplasms

ClinicalTrials.gov record

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

NCT02669914 · TERMINATED · phase2

Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast, Cancer of the Breast, Gastroesophageal Cancer, Pancreatic Cancer, Cancer of the...

ClinicalTrials.gov record

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

NCT02711345 · TERMINATED · phase1

Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma, Melanoma, Other Solid Tumors

ClinicalTrials.gov record

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

NCT02713529 · COMPLETED · phase1, phase2

Pancreatic Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer

ClinicalTrials.gov record

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

NCT02728596 · COMPLETED · na

Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer, Stage I Colorectal Cancer, Stage IA Breast Cancer, Stage IA Non-Small...

ClinicalTrials.gov record

Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer

NCT02762877 · TERMINATED · Phase not reported

Non Small Cell Lung Carcinoma

ClinicalTrials.gov record

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

NCT02770014 · TERMINATED · phase2

Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer

ClinicalTrials.gov record

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

NCT02888743 · ACTIVE NOT RECRUITING · phase2

Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IVA Colorectal...

ClinicalTrials.gov record

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

NCT02923349 · COMPLETED · phase1, phase2

Advanced Malignancies, Metastatic Cancer

ClinicalTrials.gov record

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

NCT02983045 · COMPLETED · phase1, phase2

Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer

ClinicalTrials.gov record

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

NCT02988817 · COMPLETED · phase1, phase2

Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Non Small Cell Lung Cancer (NSCLC), Thyroid Cancer, Melanoma, Sarcoma, Solid Tumors

ClinicalTrials.gov record

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

NCT03126110 · COMPLETED · phase1, phase2

Advanced Malignancies, Metastatic Cancer

ClinicalTrials.gov record

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03132922 · ACTIVE NOT RECRUITING · phase1

Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell...

ClinicalTrials.gov record

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

NCT03154190 · COMPLETED · na

Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma, Head and Neck Carcinoma, HER2/Neu Negative, Hormone-Resistant...

ClinicalTrials.gov record

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

NCT03190174 · COMPLETED · phase1, phase2

Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma,...

ClinicalTrials.gov record

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

NCT03233724 · TERMINATED · phase1, phase2

Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas

ClinicalTrials.gov record

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

NCT03241173 · COMPLETED · phase1, phase2

Advanced Malignancies

ClinicalTrials.gov record

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

NCT03261947 · COMPLETED · phase2

Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung

ClinicalTrials.gov record

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

NCT03277352 · TERMINATED · phase1, phase2

Advanced Malignancies, Metastatic Cancer

ClinicalTrials.gov record

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

NCT03576131 · TERMINATED · phase1, phase2

Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma, Gastric Cancer, Pancreatic Cancer, Urothelial Cancer

ClinicalTrials.gov record

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982 · TERMINATED · phase1

Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma,...

ClinicalTrials.gov record

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

NCT03689192 · COMPLETED · phase1

Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Metastatic...

ClinicalTrials.gov record

[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

NCT03724253 · TERMINATED · phase2

Breast Cancer, Prostate Cancer, Colorectal Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer

ClinicalTrials.gov record

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

NCT03735680 · COMPLETED · phase2

Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Urothelial Carcinoma, Non-small Cell Lung Cancer

ClinicalTrials.gov record

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance

NCT03833934 · COMPLETED · Phase not reported

Non-Small Cell Lung Cancer

ClinicalTrials.gov record

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

NCT03881488 · TERMINATED · phase1

Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer

ClinicalTrials.gov record

A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

NCT03948763 · TERMINATED · phase1

Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

ClinicalTrials.gov record

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NCT04068896 · COMPLETED · phase1, phase2

Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer,...

ClinicalTrials.gov record

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

NCT04165031 · TERMINATED · phase1, phase2

Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer

ClinicalTrials.gov record

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

NCT04234113 · TERMINATED · phase1

Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma,...

ClinicalTrials.gov record

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

NCT04256707 · COMPLETED · phase1, phase2

Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors

ClinicalTrials.gov record

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

NCT04267575 · UNKNOWN · na

Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Cancer,...

ClinicalTrials.gov record

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

NCT04299048 · COMPLETED · phase1

Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer

ClinicalTrials.gov record

Neoadjuvant Immunotherapy in Brain Metastases

NCT04434560 · TERMINATED · phase2

Brain Metastases, Adult

ClinicalTrials.gov record

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

NCT04442126 · TERMINATED · phase1, phase2

Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck...

ClinicalTrials.gov record

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

NCT04628780 · TERMINATED · phase1

Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma

ClinicalTrials.gov record

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

NCT04803305 · COMPLETED · phase1

Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Loss of Appetite, Fatigue, Cachexia, Anorexia

ClinicalTrials.gov record

Alvopem® (Pemetrexed) Safety Assessment

NCT04843007 · COMPLETED · Phase not reported

Non Small Cell Lung Cancer, Malignant Pleural Mesothelioma

ClinicalTrials.gov record

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

NCT04844073 · TERMINATED · phase1, phase2

Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer

ClinicalTrials.gov record

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017 · COMPLETED · phase1

Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer,...

ClinicalTrials.gov record

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

NCT04914897 · TERMINATED · phase2

Pleural Mesothelioma, Non-small Cell Lung Cancer

ClinicalTrials.gov record

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

NCT04985604 · TERMINATED · phase2

Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid...

ClinicalTrials.gov record

Milademetan in Advanced/Metastatic Solid Tumors

NCT05012397 · TERMINATED · phase2

Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma, Lung Adenocarcinoma, Bladder Urothelial Carcinoma, Stomach Adenocarcinoma, Breast Cancer Invasive, Ovarian...

ClinicalTrials.gov record

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

NCT05061537 · TERMINATED · phase1

Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell...

ClinicalTrials.gov record

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

NCT05070247 · TERMINATED · phase1, phase2

Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and...

ClinicalTrials.gov record

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

NCT05091528 · TERMINATED · phase1, phase2

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer

ClinicalTrials.gov record

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

NCT05194735 · TERMINATED · phase1, phase2

Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm,...

ClinicalTrials.gov record

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

NCT05256381 · TERMINATED · phase2

Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma, Castration-resistant Prostate Cancer, Ovarian Cancer

ClinicalTrials.gov record

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

NCT05259696 · COMPLETED · phase1, phase2

Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ,...

ClinicalTrials.gov record

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

NCT05397171 · TERMINATED · phase1, phase2

Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung

ClinicalTrials.gov record

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

NCT05451849 · TERMINATED · phase1, phase2

Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic...

ClinicalTrials.gov record

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

NCT05546476 · COMPLETED · phase2

Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite, Fatigue, Cachexia

ClinicalTrials.gov record

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

NCT05551117 · TERMINATED · phase2

Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory...

ClinicalTrials.gov record

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NCT05714553 · TERMINATED · phase1, phase2

Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer, Melanoma, Classical Hodgkin Lymphoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial...

ClinicalTrials.gov record

A Study to Investigate 14C-bemcentinib in Healthy Male Subjects

NCT06469138 · COMPLETED · phase1

Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Metastatic Pancreatic Cancer, Glioblastoma, Malignant Mesothelioma, COVID-19

ClinicalTrials.gov record

Disease and treatment settings

ABRAXANE: metastatic Non-small cell lung cancer (first-line)

Disease and treatment setting

1.2 Non-Small Cell Lung Cancer ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or...

ALECENSA: Non-small cell lung cancer with ALK Positive, ALK stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

1.1 Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer (NSCLC) ALECENSA is indicated as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung...

ALECENSA: Non-small cell lung cancer with ALK stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE ALECENSA is a kinase inhibitor indicated for: adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node...

Alimta: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE ALIMTA ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung...

Alimta: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration (first-line) after prior therapy

Disease and treatment setting

1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) ALIMTA ® is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer...

Alunbrig: metastatic Non-small cell lung cancer with ALK stated without a specific alteration

Disease and treatment setting

ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

ALYMSYS: unresectable metastatic Non-small cell lung cancer (first-line)

Disease and treatment setting

1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer Alymsys, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic...

Augtyro: metastatic Non-small cell lung cancer with ROS1 stated without a specific alteration

Disease and treatment setting

1.1 ROS1 -Positive Non-Small Cell Lung Cancer AUGTYRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) [see Dosage and Administration (2.1) ] .

Avastin: unresectable metastatic Non-small cell lung cancer (first-line)

Disease and treatment setting

1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer Avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic...

AVGEMSI: metastatic Non-small cell lung cancer (first-line)

Disease and treatment setting

1.3 Non-Small Cell Lung Cancer AVGEMSI in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).

AXTLE: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE AXTLE is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer...

AXTLE: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration (first-line) after prior therapy

Disease and treatment setting

1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) AXTLE is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC),...

BEIZRAY: metastatic Non-small cell lung cancer after prior therapy

Disease and treatment setting

1.2 Non-small Cell Lung Cancer BEIZRAY as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.

BEIZRAY: unresectable metastatic Non-small cell lung cancer

Disease and treatment setting

BEIZRAY in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.

BEIZRAY: unresectable metastatic Non-small cell lung cancer (adjuvant) after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE BEIZRAY is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment...

Bizengri: unresectable metastatic Lung cancer after prior therapy

Disease and treatment setting

Treatment of adults with advanced unresectable or metastatic nonsmall cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.

BIZENGRI: unresectable metastatic Non-small cell lung cancer after prior therapy

Disease and treatment setting

1.1 Advanced Unresectable or Metastatic NRG1 Fusion-Positive Non-Small Cell Lung Cancer BIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin...

BIZENGRI: unresectable metastatic Non-small cell lung cancer with HER2 stated without a specific alteration after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 )...

BRAFTOVI: metastatic Non-small cell lung cancer with BRAF V600E

Disease and treatment setting

1.3 BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) BRAFTOVI is indicated, in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF...

CYRAMZA: metastatic Non-small cell lung cancer after prior therapy

Disease and treatment setting

in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy.

CYRAMZA: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration (first-line)

Disease and treatment setting

1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon...

Datroway: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration after prior therapy

Disease and treatment setting

Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.

Docetaxel: metastatic Non-small cell lung cancer after prior therapy

Disease and treatment setting

1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.

Docetaxel: unresectable metastatic Non-small cell lung cancer

Disease and treatment setting

Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.

Docetaxel: unresectable metastatic Non-small cell lung cancer (adjuvant) after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as...

DOCIVYX: metastatic Non-small cell lung cancer after prior therapy

Disease and treatment setting

1.2 Non-small Cell Lung Cancer DOCIVYX as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.

DOCIVYX: unresectable metastatic Non-small cell lung cancer

Disease and treatment setting

DOCIVYX in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.

DOCIVYX: unresectable metastatic Non-small cell lung cancer (adjuvant) after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE DOCIVYX is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant...

EGFR-mutated advanced non-small cell lung cancer

Disease and treatment setting

Previously untreated locally advanced or metastatic non-small cell lung cancer with an activating EGFR exon 19 deletion or exon 21 L858R substitution.

Emrelis: metastatic Non-small cell lung cancer with MET stated without a specific alteration after prior therapy

Disease and treatment setting

Treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved...

Enhertu: unresectable metastatic Non-small cell lung cancer with HER2 Mutant, HER2 stated without a specific alteration, ERBB2 stated without a specific alteration after prior ther

Disease and treatment setting

1.4 HER2-Mutant Unresectable or Metastatic Non-Small Cell Lung Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have...

ENSACOVE: metastatic Non-small cell lung cancer with ALK stated without a specific alteration

Disease and treatment setting

ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test who have...

Exkivity: metastatic Non-small cell lung cancer with EGFR exon 20 insertion after prior therapy

Disease and treatment setting

Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based...

Gavreto: metastatic Non-small cell lung cancer with RET fusion

Disease and treatment setting

Treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test

Gavreto: metastatic Non-small cell lung cancer with RET Fusion, RET fusion

Disease and treatment setting

1.1 Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

Gavreto: metastatic Non-small cell lung cancer with RET stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).

Gemcitabine: metastatic Non-small cell lung cancer (first-line)

Disease and treatment setting

1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung...

Gilotrif: metastatic Non-small cell lung cancer with EGFR Mutation, EGFR stated without a specific alteration (first-line)

Disease and treatment setting

1.1 EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor...

Gilotrif: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, EGFR mutations (first-line) after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations...

Hernexeos: unresectable metastatic Non-small cell lung cancer with HER2 stated without a specific alteration, ERBB2 stated without a specific alteration

Disease and treatment setting

Treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test

Hernexeos: unresectable metastatic Non-small cell lung cancer with HER2 stated without a specific alteration, ERBB2 stated without a specific alteration after prior therapy

Disease and treatment setting

Treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA approved test, and who have...

Hyrnuo: metastatic Non-small cell lung cancer with HER2 stated without a specific alteration, ERBB2 stated without a specific alteration

Disease and treatment setting

Treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test

Hyrnuo: metastatic Non-small cell lung cancer with HER2 stated without a specific alteration, ERBB2 stated without a specific alteration after prior therapy

Disease and treatment setting

Treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and...

IBTROZI: metastatic Non-small cell lung cancer with ROS1 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE IBTROZI ® (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) [see Dosage and Administration ( 2.1 )] .

IMFINZI: resectable Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration (neoadjuvant) after prior therapy

Disease and treatment setting

• in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm...

IMJUDO: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration

Disease and treatment setting

• in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic...

IRESSA: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration (first-line)

Disease and treatment setting

1 INDICATIONS AND USAGE IRESSA is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R)...

JIDEYTRO: metastatic Non-small cell lung cancer with ROS1 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor [see Dosage and...

JOBEVNE: unresectable metastatic Non-small cell lung cancer (first-line)

Disease and treatment setting

1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer Jobevne, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic...

KEYTRUDA QLEX: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration (first-line)

Disease and treatment setting

1.2 Non-Small Cell Lung Cancer KEYTRUDA QLEX, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no...

KEYTRUDA: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration (first-line)

Disease and treatment setting

( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.

Krazati: metastatic Non-small cell lung cancer with KRAS stated without a specific alteration after prior therapy

Disease and treatment setting

Adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

LAZCLUZE: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration (first-line)

Disease and treatment setting

1 INDICATIONS AND USAGE LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor...

locally advanced Non-Small Cell Lung Cancer

Disease and treatment setting

Locally advanced unresectable tumors

Lorbrena: metastatic Non-small cell lung cancer with ALK stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

Lumakras: metastatic Non-small cell lung cancer with KRAS stated without a specific alteration after prior therapy

Disease and treatment setting

Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

Lung Carcinoma

Disease and treatment setting

Lung Carcinoma

Mekinist: metastatic Non-small cell lung cancer with BRAF V600E

Disease and treatment setting

1.3 BRAF V600E Mutation-Positive Metastatic NSCLC MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an...

MEKTOVI: metastatic Non-small cell lung cancer with BRAF V600E

Disease and treatment setting

• in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.

MVASI: unresectable metastatic Non-small cell lung cancer (first-line)

Disease and treatment setting

1.2 First-Line Non-Squamous Non-Small Cell Lung Cancer MVASI, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic...

Non-Small Cell Adenocarcinoma

Disease and treatment setting

Non-Small Cell Adenocarcinoma

Non-Small Cell Carcinoma

Disease and treatment setting

Non-Small Cell Carcinoma

Non-Small Cell Lung Cancer

Disease and treatment setting

Non-Small Cell Lung Cancer

OPDIVO QVANTIG: metastatic Non-small cell lung cancer after prior therapy

Disease and treatment setting

1.6 Metastatic Non-Small Cell Lung Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

OPDIVO QVANTIG: resectable Non-small cell lung cancer (neoadjuvant)

Disease and treatment setting

1.4 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node...

OPDIVO QVANTIG: resectable Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration (neoadjuvant) after prior therapy

Disease and treatment setting

1.5 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4...

OPDIVO: resectable Non-small cell lung cancer (neoadjuvant)

Disease and treatment setting

1.3 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive)...

OPDIVO: resectable Non-small cell lung cancer with EGFR mutations, ALK rearrangements (neoadjuvant) after prior therapy

Disease and treatment setting

• adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by...

OPDIVO: resectable Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration (neoadjuvant) after prior therapy

Disease and treatment setting

1.4 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or...

PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND: metastatic Non-small cell lung cancer (first-line)

Disease and treatment setting

1.2 Non-Small Cell Lung Cancer Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with...

Paclitaxel: metastatic Non-small cell lung cancer (first-line)

Disease and treatment setting

1.2 Non-Small Cell Lung Cancer Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with...

PEMETREXED DIPOTASSIUM: metastatic Non-small cell lung cancer (first-line) after prior therapy

Disease and treatment setting

1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Pemetrexed for Injection is indicated for: in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. as a single...

PEMETREXED: metastatic Non-small cell lung cancer

Disease and treatment setting

• In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC).

Pemetrexed: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE Pemetrexed Injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small...

Pemetrexed: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration (first-line) after prior therapy

Disease and treatment setting

1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Pemetrexed Injection is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung...

Pemfexy: metastatic Non-small cell lung cancer

Disease and treatment setting

in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC).

Pemfexy: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration (first-line) after prior therapy

Disease and treatment setting

1.1 Non-squamous Non-Small Cell Lung Cancer PEMFEXY ™ is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with...

PEMRYDI RTU: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration

Disease and treatment setting

INDICATIONS AND USAGE PEMRYDI RTU ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung...

PEMRYDI RTU: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration, ALK stated without a specific alteration (first-line) after prior therapy

Disease and treatment setting

1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) PEMRYDI RTU ® is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer...

Retevmo: metastatic Non-small cell lung cancer with RET fusion

Disease and treatment setting

Adult patients with metastatic RET fusion-positive Non-Small Cell Lung Cancer (NSCLC)

RETEVMO: metastatic Non-small cell lung cancer with RET Fusion, RET stated without a specific alteration

Disease and treatment setting

1.1 RET Fusion-Positive Non-Small Cell Lung Cancer RETEVMO ® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene...

RETEVMO: metastatic Non-small cell lung cancer with RET stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as...

Rozlytrek: metastatic Non-small cell lung cancer with ROS1 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE ROZLYTREK is a kinase inhibitor indicated for the treatment of: Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Rybrevant Faspro: metastatic Non-small cell lung cancer with EGFR Exon 19 Deletion, EGFR stated without a specific alteration (first-line)

Disease and treatment setting

1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or...

Rybrevant: metastatic Lung cancer with EGFR stated without a specific alteration after prior therapy

Disease and treatment setting

Treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA approved test, whose disease has...

Rybrevant: metastatic Non-small cell lung cancer with EGFR Exon 19 Deletion, EGFR stated without a specific alteration (first-line)

Disease and treatment setting

1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or...

Rybrevant: metastatic Non-small cell lung cancer with MET stated without a specific alteration, EGFR stated without a specific alteration (first-line)

Disease and treatment setting

1 INDICATIONS AND USAGE RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic...

Stage 0 Non-Small Cell Lung Cancer

Disease and treatment setting

Treatment of Stage 0 NSCLC

Stage I Non-Small Cell Lung Cancer

Disease and treatment setting

Treatment of Stage I Non-Small Cell Lung Cancer

Stage IB Non-Small Cell Lung Cancer

Disease and treatment setting

Adjuvant targeted therapy (for patients with stage IB NSCLC and EGFR variants)

Stage II Non-Small Cell Lung Cancer

Disease and treatment setting

Treatment of Stage II Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer

Disease and treatment setting

Treatment of Stage IIIA NSCLC

Stage IIIA Non-Small Cell Lung Cancer

Disease and treatment setting

Treatment Options for Resected/Resectable Stage IIIA NSCLC

Stage IIIA Non-Small Cell Lung Cancer

Disease and treatment setting

Treatment Options for Unresectable Stage IIIA NSCLC

Stage IIIB Non-Small Cell Lung Cancer

Disease and treatment setting

Treatment of Stage IIIB and Stage IIIC Non-Small Cell Lung Cancer

Stage IV recurrent Non-Small Cell Lung Cancer

Disease and treatment setting

Treatment of Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC

Stage IV recurrent Non-Small Cell Lung Cancer

Disease and treatment setting

Treatment of Progressive Stage IV, Relapsed, and Recurrent NSCLC

TABRECTA: metastatic Non-small cell lung cancer with MET stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as...

Tafinlar: metastatic Non-small cell lung cancer with BRAF V600E

Disease and treatment setting

( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.

TAGRISSO: Non-small cell lung cancer with EGFR Mutation, EGFR stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

1.1 Adjuvant Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal...

TAGRISSO: Non-small cell lung cancer with EGFR stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

• adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Tecentriq Hybreza: metastatic Non-small cell lung cancer with PD-L1 stated without a specific alteration, EGFR stated without a specific alteration, ALK stated without a specific a

Disease and treatment setting

TECENTRIQ HYBREZA, as monotherapy, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or...

Tecentriq Hybreza: Non-small cell lung cancer with PD-L1 stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

1.1 Non-Small Cell Lung Cancer TECENTRIQ HYBREZA, as monotherapy, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA [see Clinical Studies (14.1) ] non-small...

TECENTRIQ: metastatic Non-small cell lung cancer with PD-L1 stated without a specific alteration, EGFR stated without a specific alteration, ALK stated without a specific alteratio

Disease and treatment setting

TECENTRIQ, as a single agent, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1...

TECENTRIQ: Non-small cell lung cancer with PD-L1 stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

1.1 Non-Small Cell Lung Cancer TECENTRIQ, as a single-agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA [see Clinical Studies (14.1) ] non-small cell...

TECENTRIQ: Non-small cell lung cancer with PD-L1 stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with...

Tepmetko: metastatic Non-small cell lung cancer with MET stated without a specific alteration

Disease and treatment setting

Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

Vegzelma: unresectable metastatic Non-small cell lung cancer (first-line)

Disease and treatment setting

1.2 First-Line Non-Squamous Non-Small Cell Lung Cancer VEGZELMA, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic...

Vizimpro: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration (first-line)

Disease and treatment setting

VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations...

Xalkori: metastatic Non-small cell lung cancer with ALK stated without a specific alteration, ROS1 Positive, ROS1 positive

Disease and treatment setting

1.1 ALK- or ROS1-Positive Metastatic Non-Small Cell Lung Cancer XALKORI is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or...

YERVOY: metastatic Non-small cell lung cancer with PD-L1 stated without a specific alteration, EGFR stated without a specific alteration, ALK stated without a specific alteration (

Disease and treatment setting

1.6 Metastatic Non-Small Cell Lung Cancer YERVOY, in combination with nivolumab, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as...

Zegfrovy: metastatic Non-small cell lung cancer with EGFR stated without a specific alteration

Disease and treatment setting

Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test

Zirabev: unresectable metastatic Non-small cell lung cancer (first-line)

Disease and treatment setting

1.2 First-Line Non-Squamous Non-Small Cell Lung Cancer ZIRABEV, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic...

ZYKADIA: metastatic Non-small cell lung cancer with ALK stated without a specific alteration

Disease and treatment setting

ZYKADIA is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

Drug labels

ABRAXANE

Label date 2022-10-31

ABRAXANE is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should...

DailyMed label

ALECENSA

Label date 2026-08-21

ALECENSA is a kinase inhibitor indicated for: adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive) as detected by...

DailyMed label

Alimta

Label date 2023-05-19

ALIMTA ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR...

DailyMed label

Alunbrig

Label date 2026-01-12

ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . ALUNBRIG...

DailyMed label

Augtyro

Label date 2024-06-13

AUGTYRO is a kinase inhibitor indicated for the treatment of • adult patients with locally advanced or metastatic ROS1- positive non-small cell lung cancer (NSCLC). ( 1.1 ) • adult and pediatric patients 12 years of age and older with...

DailyMed label

AVGEMSI

Label date 2026-07-27

AVGEMSI is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination...

DailyMed label

AXTLE

Label date 2025-10-08

AXTLE is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or...

DailyMed label

BEIZRAY

Label date 2025-12-17

BEIZRAY is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable...

DailyMed label

BIZENGRI

Label date 2025-01-17

BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fusion with disease...

DailyMed label

BIZENGRI

Label date 2026-05-19

BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fusion with disease...

DailyMed label

CYRAMZA

Label date 2026-06-09

CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal...

DailyMed label

Docetaxel

Label date 2024-08-22

Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of...

DailyMed label

Docetaxel

Label date 2024-08-01

Docetaxel Injection is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable...

DailyMed label

Docetaxel

Label date 2025-01-31

Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of...

DailyMed label

DOCETAXEL

Label date 2024-08-15

Docetaxel Injection is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of...

DailyMed label

Docetaxel

Label date 2024-09-19

Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of...

DailyMed label

Docetaxel

Label date 2023-11-07

1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as...

DailyMed label

Docetaxel

Label date 2025-01-20

Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of...

DailyMed label

Docetaxel

Label date 2024-12-06

Docetaxel is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable...

DailyMed label

Docetaxel

Label date 2025-01-20

Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of...

DailyMed label

Docetaxel

Label date 2021-02-04

DOCETAXEL INJECTION is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable...

DailyMed label

Docetaxel

Label date 2023-11-21

1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as...

DailyMed label

DOCIVYX

Label date 2025-07-15

DOCIVYX is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable...

DailyMed label

EMRELIS

Label date 2025-05-25

EMRELIS is indicated for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as...

DailyMed label

ENSACOVE

Label date 2026-02-17

ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)as detected by an FDA-approved test [see Dosage and Administration...

DailyMed label

Gavreto

Label date 2025-12-05

GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC). ( 1.1 ) Adult and...

DailyMed label

Gavreto

Label date 2025-12-30

GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC). ( 1.1 ) Adult and...

DailyMed label

GEMCITABINE

Label date 2023-09-11

Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 )...

DailyMed label

Gemcitabine

Label date 2026-04-27

Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 )...

DailyMed label

Gemcitabine

Label date 2026-04-27

Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 )...

DailyMed label

Gilotrif

Label date 2025-11-13

GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an...

DailyMed label

HERNEXEOS

Label date 2026-08-13

HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an...

DailyMed label

HYRNUO

Label date 2026-03-04

HYRNUO is indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2 ) tyrosine kinase domain (TKD) activating mutations, as detected...

DailyMed label

IBTROZI

Label date 2026-03-23

IBTROZI ® (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) [see Dosage and Administration ( 2.1 )] . IBTROZI is a kinase inhibitor...

DailyMed label

IMFINZI

Label date 2026-08-31

IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after...

DailyMed label

IMJUDO

Label date 2026-08-31

IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: • in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.1 ) • in...

DailyMed label

IRESSA

Label date 2023-02-28

IRESSA is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as...

DailyMed label

JIDEYTRO

Label date 2026-07-22

JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor [see Dosage and Administration ( 2.1 ), Clinical...

DailyMed label

KEYTRUDA

Label date 2026-07-10

KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and...

DailyMed label

KEYTRUDA QLEX

Label date 2026-07-31

KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or...

DailyMed label

KRAZATI

Label date 2026-03-25

KRAZATI is an inhibitor of the RAS GTPase family indicated for: Non-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by...

DailyMed label

LAZCLUZE

Label date 2026-05-05

LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions...

DailyMed label

Lorbrena

Label date 2026-06-26

LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. LORBRENA is a kinase...

DailyMed label

Lorbrena

Label date 2026-02-13

LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. LORBRENA is a kinase...

DailyMed label

LUMAKRAS

Label date 2025-01-22

LUMAKRAS is an inhibitor of the RAS GTPase family indicated for: KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally...

DailyMed label

MEKTOVI

Label date 2025-03-20

MEKTOVI is a kinase inhibitor indicated: • in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) •...

DailyMed label

OPDIVO

Label date 2026-08-12

OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination...

DailyMed label

Paclitaxel

Label date 2023-11-01

Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or...

DailyMed label

PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND

Label date 2023-05-01

Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or...

DailyMed label

Pemetrexed

Label date 2022-12-01

Pemetrexed Injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC),...

DailyMed label

PEMETREXED

Label date 2025-10-08

Pemetrexed Injection is a folate analog metabolic inhibitor indicated: • In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC). ( 1.1 )...

DailyMed label

Pemetrexed

Label date 2025-12-16

Pemetrexed Injection is a folate analog metabolic inhibitor indicated: • in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC),...

DailyMed label

Pemetrexed

Label date 2024-11-28

Pemetrexed Injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC),...

DailyMed label

PEMETREXED

Label date 2024-07-24

Pemetrexed Injection is a folate analog metabolic inhibitor indicated: • In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC). ( 1.1 )...

DailyMed label

PEMETREXED DIPOTASSIUM

Label date 2025-02-05

Pemetrexed for Injection is a folate analog metabolic inhibitor indicated: in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the...

DailyMed label

Pemfexy

Label date 2026-06-18

PEMFEXY™ is a folate analog metabolic inhibitor indicated for: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor...

DailyMed label

Pemfexy

Label date 2026-02-20

PEMFEXY™ is a folate analog metabolic inhibitor indicated for: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor...

DailyMed label

PEMRYDI RTU

Label date 2025-07-08

1. INDICATIONS AND USAGE PEMRYDI RTU ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung...

DailyMed label

Photofrin

Label date 2026-04-28

PHOTOFRIN is a photoactivated radical generator indicated for: Esophageal Cancer ( 1.1 ) Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the...

DailyMed label

Rozlytrek

Label date 2025-12-04

ROZLYTREK is a kinase inhibitor indicated for the treatment of: Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1.1 ) Adult and pediatric patients older than 1...

DailyMed label

Rybrevant

Label date 2025-11-11

RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer...

DailyMed label

Rybrevant Faspro

Label date 2026-06-17

RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of...

DailyMed label

TABRECTA

Label date 2025-12-15

TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an...

DailyMed label

TAGRISSO

Label date 2024-09-25

TAGRISSO is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21...

DailyMed label

TECENTRIQ

Label date 2026-05-20

TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC...

DailyMed label

Tecentriq Hybreza

Label date 2026-05-20

TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and...

DailyMed label

TEPMETKO

Label date 2025-04-17

TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. TEPMETKO is a kinase inhibitor indicated for...

DailyMed label

Vizimpro

Label date 2026-06-23

VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an...

DailyMed label

Xalkori

Label date 2025-07-22

XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. (...

DailyMed label

ZYKADIA

Label date 2025-12-15

ZYKADIA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test [see Dosage and Administration...

DailyMed label